Abstract

Among several requirements for the manufacture of Advanced Therapy Medicinal Products (ATMP) are: following the guidelines of a pharmaceutical quality system, complying with Good Manufacturing Practice (GMP) and access to a cleanroom fulfilling strict environmental conditions (Class A work area and Class B environment). This makes ATMP expensive. Moreover, the production of many of these therapeutic products may also be unprofitable, as in most cases their use is limited to a few patients and to a single batch per manufacturing unit. To reduce costs, ATMP may be produced in a scaled-down system isolated from the external environment (isolator), allowing for placement of this facility in a Class D environment, which is much more permissive and less costly. In this work, we confirm that it is possible to manufacture bioengineered corneal epithelium inside an isolator while fulfilling all the safety assurance standards at an affordable cost for patients. This small-scale ultra-clean working environment complies with GMP guidelines and could be a solution for the high costs associated with conventional cleanroom ATMP production.

Highlights

  • Advanced Therapy Medicinal Products (ATMP) for human use include gene therapy, cell therapy and tissue engineering products

  • Together with our Pharmacy Service, in the present study we developed a mini cleanroom with all the equipment necessary to manufacture a bioengineered corneal epithelium (PRGF scaffold with cultured Limbal Stem Cells (LSC) on top)

  • The mini cleanroom consisted of an isolator of positive pressure International Organization for Standardization (ISO) 4 (AISLAISO4-PP1800®, TDI, Madrid, Spain) of exterior dimensions 1880 × 780 × 1620 cm, equipped with a lateral Special Airlock System (SAS) with an independent ultraviolet (UV) sterilization system and a double-door lock along with a gas outlet with an electronically controlled valve and Universal serial bus (USB), High-Definition Multimedia Interface (HDMI) and alternative current/discontinuous current (AC/DC) connectors

Read more

Summary

Introduction

Advanced Therapy Medicinal Products (ATMP) for human use include gene therapy, cell therapy and tissue engineering products. These ATMP offer treatment options for diseases that today lack effective medication. The in vitro expansion of LSC has shown satisfactory results, and Holoclar® (Chiesi, Parma, Italy) is the first ATMP used in Europe to treat LSCD after the European Medicine Agency (EMA) granted it marketing authorization [1]. The Spanish Fundación de Investigación Oftalmológica developed a simple culture method for the in vitro expansion of LSC avoiding xenogeneic components, in which Plasma Rich in Growth Factors (PRGF) is used as the only culture medium supplement and to construct a PRGF membrane to culture and transplant the LSC [3]. Under current European legislation, this form of therapy is defined as an ATMP

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call